Zusammenfassung
Bereits im Jahre 1967 fasste Pearse Zellen unter dem Begriff APUD Zellsysteme zusammen (“amine and precursor uptake and decarboxylation”), die die Fähigkeit besitzen, aromatische Amine zu synthetisieren, Vorstufen der Amine aufzunehmen und Aminosäuren mittels eines Enzyms zu den entsprechenden Aminen zu decarboxylieren. Aufgrund der Beobachtung, dass die in diesen Zellen synthetisierten Peptidhormone auch im Zentralnervensystem von funktioneller Bedeutung sind und immunhistochemische Markerenzyme ebenfalls in bei den Zellsystemen nachweisbar sind, wurde der erweiterte Terminus des neuroendokrinen Systems eingeführt. Das diffuse neuroendokrine System umschließt hierbei die neuroendokrinen Zellen, die nicht in makroskopisch kompakten Organen zusammengelagert sind. Im Bereich des Gastrointestinaltraktes konnten mittlerweile 15 verschiedene Zelltypen des diffusen neuro endokrinen Systems sowie eine Reihe der von ihnen produzierten Hormone identifiziert werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Literatur zu Abschn. 14.1
Green D.W., Gomez G., Greeley G.H. Jr (1989) Gastrointestinal peptides. Gastroenterol Clin North Am 18(4):695–733
Modlin I.M., Basson M.D. (1993) Clinical applications of gastrointestinal hormones. Endocrinol Metab Clin North Am 22(4):823–844
Solcia E., Fiocca R., Rindi G., Villani L., Cornaggia M., Capella C. (1993) The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 22(4):795–821
Literatur zu Abschn. 14.2
Ahlman H., Wangberg B., Nilsson O. (1993) Growth regulation in carcinoid tumors. Endocrinol Metab Clin North Am 22(4):889–915
Arnold R., Benning R., Neuhaus C., Rolwage M., Trautmann M.E. (1993) Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54(Suppl 1): 72–75
Arnold R., Trautmann M.E., Creutzfeldt W. et al. (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38(3):430–438
Bukowsky R.M., Johnson K.G., Peterson R.F., Stephens R.L., Rivkin S.E., Neilan B., Constanzi J.H. (1987) A phase II trail of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60(12):2891–2895
Bukowski R.M., Stephens R., Oishi N. (1983) Phase II trial of 5-FU.Adriamycin, cyclophosphamide, and streptozotocin in metastatic carcinoid. Proc Am Soc Clin Oncol 2: 130
Burkowsky R.M., Tangen C.M., Peterson R.F. et al. (1994) Phase II trial of dimethyltriazenoimidazole carboxiamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 73(5):1505–1508
Caplin M.E., Buscombe J.R., Hilson A.J., Jones A.L., Watkinson A.F., Burroughs A.K. (1989) Carcinoid tumor. Lancet 352(9130):799–805
Casper E.S., Mittelman A., Kelson D., Young C.W. (1982) Phase I clinical trial of tludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15(3):233–235
Clouse M.E., Perry L., Stuart K., Stokes K.R. (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55(Suppl 3):92–97
Creutzfeldt W. (1994) Historical background and natural history of carcinoids. Digestion 55(Suppl 3):3–10
di Bartolomeo M., Bajetta E., Buzzoni R. et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77(2):402–408
Godwin J.D. (1975) Carcinoid tumors: an analysis of 2837 cases. Cancer 36: 560–569
Frank M., Klose K.I., Wied M., Ishaque N., Schade-Brittinger C., Arnold R. (1999) Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94(5):1381–1387
Janson E.T., Ronnblom L., Ahlstrom H., Grander D., Alm G., Einhorn S., Oberg K. (1992) Treatment with alpha-interferon versus Alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3(8):635–638
Kelsen D.P., Cheng E., Kemeny N. (1982) Streptozotocin and adriamycin in the treatment of apud tumors. Proc Am Assoc Cancer Res 23: 433
Lamberts S.W., van der Lely A.J., de Herder W.W., Hotland L.J. (1996) Octreotide. N Engl J Med 334(4):246–254
Moertel C.G., Hanley J.A. (1979) Combination chemotherapy trails in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2(4):327–334
Moertel C.G., Hanley J.A., Johnson L.A.N. (1980) Streptozocin alone compared with streptozocin plus flourouracil in the treatment of advanced islet-cell carcinoma. Engl J Med 303(21):1189–1194
Moertel C.G., Kvols L.K., O’Connell M.J., Rubin J. (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2):227–232
Neijt J.P., Lacave A.J., Splinter T.A., Taal B.G., Veenhof C.H., Sahmoud T., Lips C.J. (1995) Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperation Group. Br J Cancer 71(1):106–108
Newton J.N., Swerdlow A.J., dos Santos Silva I.M., Vessey M.P., Grahame Smith D.G., Primatesta P., Reynolds D.J. (1994) The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 70(5):939 942
Norheim I., Öberg K., Theodorsson Norheim E et al. (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206(2):115–125
Oberg K. (1994) Treatment of neuroendocrine tumors. Cancer Treat Rev 20: 331–355
Olney J.R., Urdaneta L.F., Al Jurf A.S., Jochimsen P.R., Shirazi S.S. (1985) Carcinoid tumors of the gastrointestinal tract. Am Surg 51(1):37–41
Otte A., Mueller-Brand J., Dellas S., Nitzsche E.U., Herrmann R., Maecke H.R. (1998) Yttrium-90-labelled somatostatinanalogue for cancer treatment (letter). Lancet 51(9100):417–418
Pearse A.G.E. (1967) The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, histologic cells of the APUD se ries and the embryologic, histologic and pathologic implications of the concept. J Histochem Cytochem 17: 303–313
Roggo A., Wood W.C., Ottinger L.W. (1993) Carcinoid tumors of the appendix. Ann Surg 217(4):385–390
Rothmund M., Stinner B., Arnold R. (1991) Endocrine pancreatic carcinoma. Eur J Surg Oncol 17(2):191–199
Rubin J., Ajani J., Schirmer W. et al. (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17(2):600–606
Sanders C. (1970) Autopsy report. Tex Rep Biol Med 28(3):177–178
Shaw P.A. (1990) Carcinoid tumours of the appendix are different. J Pathol 162(3):189–190
Saltz L., Lauwers G., Wiseberg J., Kelsen D. (1993) A phase II trial of carboplatin in patients with advanced APUD tumors. Cancer 72(2):619–622
Saltz L., Kemeny N., Schwartz G., Kelsen D. (1994) A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74(3):958–961
Verner J., Morrison A.B. (1974) Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 133(3):492–499
Ziegler R., Piekardt C.R., Willig R.P. (1993) Karzinoid. In: Deutsche Gesellschaft für Endokrinologie (Hrsg) Rationelle Diagnostik in der Endokrinologie. Thieme, Stuttgart, p 118
Literatur zu Abschn. 14.3
Fishbeyn V.A., Norton J.A., Benya R.V., Pisegna J.R., Venzon D.J., Metz D.C., Jensen R.T. (1993) Assessment and predietion of long-term eure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med 119(3):199–206
Kaplan E.L., Horvath K., Udekwu A., Straus F., Schark C., Ferguson D.J., Skinner D.B. (1990) Gastrinomas: a 42-year experience. World J Surg 14(3):365–375; discussion 375–376
Kvols L.K., Moertel C.G., O’Connell M.J., Schutt A.J., Rubin J., Hahn R.G. (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315(11):663–666
Maton P.N., Gardner J.D., Jensen R.T. (1989) Diagnosis and management of Zollinger-Ellison syndrome. Endocrinol Metab Clin North Am 18(2): 519–543
Moertel C.G. et al. (1992) Streptozotocin-doxorubicin, streptozotocin fluoro uracil, or chlorzotocin in the treatment of advanced islet cell carcinoma. New Engl J Med 326: 519–523
Pisegna J.R.; Slimak G.G.; Doppman J.L. et-al. (1993) An evaluation of human recombinant alpha interferon in patients with metastatie gastrinoma. Gastroenterology 105(4):1179–1183
Ruszniewski P., Ramdani A., Cadiot G., Lehy T., Mignon M., Bonfils S. (1993) Long term treatment with octreotide in patients with the Zollinger Ellison syndrome. Eur J Clin Invest 23(5):296–301
von Schrenck T., Howard J.M., Doppman J.L. et-al. (1988) Prospective study of chemotherapy in patients with metastatic gastrin oma. Gastroenterology 94(6):1326–1334
Wolfe M.M., Jensen R.T. (1987) Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 317(19):1200–1209
Zollinger R.M., Ellison E.H. (1955) Pimary peptic ulcerations of the jejunum associated with islet cell tumors of the pankreas. Ann Surg 142: 709–728
Literatur zu Abschn. 14.4
Bloom-S.R.; Polak-J.M. (1980) Glucagonomas, Vipomas and Somatostatinomas. Clin Endocrinol Metabol 9: 285–297
Bloom S.R., Polak J.M. (1987) Glucagonoma syndrome. Am J Med 82(5B):25–36
Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. (1992) Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorzotocin in the treatment of advanced islet cell carcinoma. New Engl J Med 326: 519–523
Rothmund M., Stinner B., Arnold R. (1991) Endocrine pancreatic carcinoma. Eur J Surg Oncol 17(2):191–199
Stacpoole P.W. (1981) The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 2(3):347–361
Wermers R.A., Fatourechi V., Wynne A.G., Kvols L.K., Lloyd R.V. (1996) The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 75(2):53–63
Literatur zu Abschn. 14.5
Grier J.F. (1995) WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J 88(1):22–2
Kraenzlin M.E., Ch’ng J.L., Wood S.M., Carr D.H., Bloom S.R. (1985) Long-term treatment of a Vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88: 185–187
Krejs G.J. (1987) Vipoma syndrome. Am J Med 82(5B):37–48
Lundstedt C., Linjawi T., Amin T. (1994) Liver Vipoma: report of two cases and literature review. Abdom Imaging 19(5):433–437
Mekhjian H.S.; O’Dorisio T.M. (1987) Vipoma syndrome. Semin Oncol 14(3):282–291
Literatur zu Abschn. 14.6
O’Brien T.D., Chejfec G., Prinz R.A. (1993) Clinical features of duodenal somatostatinomas. Surgery 114(6):1144–1147
Somers G., Pipeleers Marichal M., Gepts W., Pipeleers D. (1983) A case of duodenal somatostatinoma: diagnostic usefulness of calcium-pentagastrin test. Gastroenterology 85(5):1192–1198
Taccagni G.L., Carlucci M., Sironi M., Cantaboni A., Di Carlo V. (1986) Duodenal somatostatinoma with psammoma bodies: an immunohistochemical and ultrastructural study. Am J Gastroenterol 81: 33–37
Vinik A.I., Strodel W.E., Eckhauser F.E., Moattari A.R., Lloyd R. (1987) Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 14(3):263–281
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Engelbach, M., Beyer, J. (2001). Neuroendokrine Tumoren des Gastrointestinaltraktes. In: Nawroth, P.P., Ziegler, R. (eds) Klinische Endokrinologie und Stoffwechsel. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56784-1_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-56784-1_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62970-9
Online ISBN: 978-3-642-56784-1
eBook Packages: Springer Book Archive